Xin Lang Cai Jing·2025-10-21 01:24Group 1 - The core point of the news is that Junshi Biosciences experienced a slight decline in stock price and significant trading activity, with notable financing and margin trading figures indicating high levels of investor engagement [1][2][3] Group 2 - On October 20, Junshi Biosciences' stock fell by 0.34%, with a trading volume of 351 million yuan. The financing buy-in amount was 28.92 million yuan, while the financing repayment was 33.51 million yuan, resulting in a net financing outflow of 4.59 million yuan [1] - As of October 20, the total financing and margin trading balance for Junshi Biosciences was 1.401 billion yuan, with the financing balance at 1.39 billion yuan, accounting for 4.69% of the circulating market value, which is above the 90th percentile of the past year [1] - In terms of margin trading, on October 20, Junshi Biosciences had 3,815 shares repaid and 2,550 shares sold short, with a short selling amount of 98,600 yuan. The remaining short selling volume was 284,500 shares, with a margin balance of 11 million yuan, also above the 90th percentile of the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] - As of June 30, 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] Group 4 - As of June 30, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares from the previous period. The E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [3] - Hong Kong Central Clearing Limited was the tenth largest circulating shareholder, holding 13.1291 million shares, a decrease of 186,650 shares from the previous period [3]